Positive Phase III results for dupilumab for patients with atopic dermatitis

French pharma giant Sanofi (Euronext: SAN) and the USA’s Regeneron Pharmaceuticals (Nasdaq: REGN) have announced positive results for two Phase III studies of dupilumab in patients with moderate-to-severe atopic dermatitis (AD) patients.

In the two placebo-controlled studies, known as LIBERTY AD SOLO 1 and SOLO 2, treatment with dupilumab as monotherapy significantly improved measures of overall disease severity, skin clearing, itching, quality of life and mental health, according to a statement.

George Yancopoulos, chief scientific officer at Regeneron, said: “These data provide strong evidence that the IL-4 and IL-13 signaling pathway is a fundamental driver of inflammation in atopic dermatitis. Dupilumab, which is the first in a new class of immunotherapies, blocked the aberrant activation in this pathway, resulting in significant efficacy without evidence of immune-suppressing side effects.”